Scientists at the National University of Singapore have discovered that cyclodextrin, a substance frequently used in food production, may help repair lymphatic vessels. The study, published in the journal Nature, suggests this additive could provide a low-cost alternative for managing lymphoedema in cancer survivors.
Dissolving cholesterol pockets to restore lymph flow
The mechanism behind this potential treatment involves the unique molecular structure of cyclodextrin, which features a hollow core capable of trapping cholesterol crystals. This specific property has already been utilized in the food industry to produce low-fat dairy products. As reported by the research team at the National University of Singapore, this same ability could be the key to addressing the inflammation that often follows cancer treatments.
The researchers found that women undergoing breast cancer surgery often have large deposits of cholesterol around the affected tissue,which creates scarring and blocks the lymphatic system. By injecting cyclodextrin,the researchers were able to dissolve these cholesterol pockets and encourage the regeneration of damaged vessels. This process moves beyond simple fluid management to address the underlying vascular blockage.
The burden on 450,000 people in the United Kingdom
Lymphoedema remains a debilitating complication for many survivors of surgery or radiotherapy. In the United Kingdom alone, more than 450,000 individuals are currently living with the condition, which often results from damaged lymph nodes in the limbs or chest. This condition creates a chronic build-up of fluid, leading to skin thickening and stiff limbs that make daily tasks difficult.
Current management strategies, such as manual lymphatic drainage massage or the use of compression stockings, require constant daily maintenance and can lead to skin irritation. While surgical options like liposuction exist, they are often prohibitively expensive and carry significant medical risks, leaving many patients without effective relief. The prospect of a food-grade additive offers a potentially more accessible path for these patients.
Eight weeks of vessel regeneration in animal models
In laboratory settings, the efficacy of cyclodextrin was demonstrated through repeated injections into animal models of the disease. The report says that over an eight-week period, these animals showed a significant reduction in both swelling size and local inflammation. Most importantly , the study observed a marked recovery in the physical structure of the lymphatic vessels.
This structural repair suggests that the additive does more than just move fluid; it may actually assist the body in repairing the damaged network responsible for carrying lymphatic waste back into the bloodstream. This finding represents a significant departure from current therapies that only manage symptoms rather than addressing the underlying structural damage caused by cancer treatments.
The transition from food additive to human clinical trials
While the results are promising, several critical questions remain before cyclodextrin becomes a standard medical treatment. It is currently unknown if the specific dosage required to dissolve cholesterol in humans will be as safe and well-tolerated as it was in animal models . Additionally, researchers must determine if the regeneration of vessels seen in the lab will translate to the complex vascular systems of human patients.
There is also the question of whether the cost-effectiveness of using a food-grade additive will hold up once it is regulated for medical use. The study has now stimulated interest among clinicians, and the research is being translated into human trials to see if this affordable additive can provide lasting relief for those living with the physical and emotional burden of the condition.
Comments 0